For this reason, one of the new frontiers in late-stage melanoma therapy could be the combination of multiple compounds that can simultaneously inhibit the MAPK and PI3K/AKT pathways to overcome the acquired resistance process with synergistic effects in inducing apoptosis. The gene discussed is PIK3CA; the disease is melanoma.